Results 171 to 180 of about 2,132,699 (356)

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source

Safety and effectiveness of hormonal vs non-hormonal or no contraception in women with hypertension and future fertility desire: A broad-scope systematic review. [PDF]

PLoS One
Losada-Trujillo N, Estrada-Orozco K, Velasco-Lancheros OJ, Ramírez-Vargas BA, Burgos-Cárdenas ÁJ, González-Caicedo PA, Hoyos Bedoya MJ, Gaitán-Duarte H.   +7 more
europepmc   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Oral Contraceptives: The Risks, Benefits, and Dilemmas

, 2010
Millions of women have chosen to use oral contraceptives for various reasons. However, the question must be raised as to the awareness level of the risks and benefits associated with the use of oral contraceptives.
West, Courtney S
core  

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Oral contraceptives and tissue factor expression. Comments on "Do combined oral contraceptives induce formation of tissue factor?" [PDF]

Res Pract Thromb Haemost
Østerud B.
europepmc   +1 more source

Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing

Drug Testing and Analysis, EarlyView.
Results confirm that the MRL of 30 ng/mL for 21‐desacetyl‐deflazacort together with a 3‐day washout period is an appropriated strategy to detect oral deflazacort administration in sport competition. ABSTRACT Deflazacort (DEF) is a glucocorticoid prohibited in sports competitions when orally administered.
Sergi Coll, Claudia Bressan, Núria Monfort, Ana Aldea‐Perona, Marcel·lí Carbó, Rosa Ventura   +5 more
wiley   +1 more source

Prevalência de uso de métodos contraceptivos e adequação do uso de anticoncepcionais orais na cidade de Pelotas, Rio Grande do Sul, Brasil

Cadernos de Saúde Pública
Através de um inquérito de prevalência de base populacional entre mulheres de 20 a 49 anos, residentes na zona urbana da cidade de Pelotas, Rio Grande do Sul, estudou-se o consumo de métodos contraceptivos. Entre as 677 mulheres, verificou-se que 455 (65,
Juvenal Soares Dias da Costa, Paula Berenhauser D'Elia, Mônica Regina Moreira   +2 more
doaj  

Knowledge, Attitude, and Practice on the Use of Contraception Among Female Outpatients in Lagos University Teaching Hospital. [PDF]

Cureus
Naiyeju OJ, Okunade KS, Soibi-Harry AP.
europepmc   +1 more source

Daily Ovarian Hormone Exposure and Loss of Control Eating in Adolescent Girls: A Stage 2 Registered Report

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This Stage 2 Registered Report examined (1) the main effects and interaction of within‐person daily associations between ovarian hormones (i.e., estrogen, progesterone) and loss of control eating (LOCE), and (2) the within‐person mediating roles of food‐related reward anticipation and response inhibition. Methods Adolescent girls (n =
Tyler B. Mason, Jeremy C. Morales, Kathryn E. Smith, Genevieve F. Dunton, Raina D. Pang   +4 more
wiley   +1 more source